Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Apilimod dimesylate (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Synta Pharmaceuticals
- 07 Jan 2010 New trial record